<DOC>
	<DOC>NCT00333775</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of 2 doses of Avastin in combination with docetaxel, versus docetaxel plus placebo, in patients with metastatic HER2 negative breast cancer who are candidates for taxane-based chemotherapy but who have not received prior chemotherapy for metastatic disease. The anticipated time on treatment is 1-2 years and the target sample size is 500+ individuals.</brief_summary>
	<brief_title>A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Five participants randomized to the docetaxel 100 mg/m^2 plus placebo group actually received docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg and are included in the docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg group for the adverse event results. Sixteen participants randomized to the docetaxel 100 mg/m^2 plus placebo group actually received docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg and are included in the docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg group for the adverse event results.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criteria: Female patients â‰¥ 18 years of age. Human epidermal growth factor receptor 2 (HER2)negative cancer of the breast with locally recurrent or metastatic disease, suitable for chemotherapy. No adjuvant chemotherapy within 6 months before randomization, and no taxanebased chemotherapy within 12 months before randomization. Eastern Cooperative Oncology Group (ECOG) performance status of 01. Exclusion criteria: Previous chemotherapy for metastatic or locally recurrent breast cancer. Radiotherapy for treatment of metastatic disease. Other primary tumors within last 5 years, except for controlled limited basal cell or squamous cancer of the skin, or cancer in situ of the cervix. Spinal cord compression or brain metastases. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization. Inadequate bone marrow, liver, or renal function. Uncontrolled hypertension.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>